Fri, Jul 25, 2014, 11:22 AM EDT - U.S. Markets close in 4 hrs 38 mins


% | $
Click the to save as a favorite.

Insmed Incorporated Message Board

checksurshorts 3650 posts  |  Last Activity: Jul 24, 2014 12:26 AM Member since: Dec 1, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    NTMir Joins NORD

    by checksurshorts Jul 23, 2014 5:56 PM
    checksurshorts checksurshorts Jul 24, 2014 12:26 AM Flag

    If the NTM trial "failed" why do you think the FDA awarded breakthrough status based upon same trial? TIA

    Sentiment: Strong Buy

  • Reply to

    Upcoming Insmed headline soon?

    by insmhistorian Jul 23, 2014 4:10 PM
    checksurshorts checksurshorts Jul 23, 2014 6:03 PM Flag

    Love it!!!

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts Jul 23, 2014 5:56 PM Flag

    "NTM Info & Research has joined the National Organization for Rare Diseases (NORD) as an associate member organization.

    A 501(c)(3) not-for-profit organization, NORD is a unique federation of health organizations dedicated to helping the more than 30 million Americans who live with a rare disease, and assisting the organizations that serve them.

    Founded by leaders of rare-disease organizations who helped shape the Orphan Drug Act, NORD is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and service.

    NORD offers several programs to help patients with rare diseases, including a Patient Assistance Program, Patient Information Center, Online Patient Communities, and State-by-State Insurance Information."

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts Jul 23, 2014 12:04 AM Flag

    From NTMir. Insmed will be there...Shire will be there.

    "A Rare Patient Advocacy Summit is being held in Huntington Beach, CA on September 11th & 12th. It is recommended for patients, caregivers, family members, patient advocates and rare disease organizations.

    The Summit is organized by The Global Gene Project, one of the leading rare disease patient advocacy organizations in the world with over 500 global organizations. Patients can attend the summit or register for the webcast. "

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts Jul 22, 2014 11:54 PM Flag

    "NTM Info & Research has joined the European Organization for Rare Diseases (EURORDIs) as an associate member organization.

    A non-governmental patient-driven alliance of organizations and individuals active in the field of rare diseases in Europe, EURORDIS supports the creation and development of rare disease national alliances and disease-specific European federations and networks. It represents over 600 rare disease patient organizations in more than 50 countries, covering more than 4000 rare diseases, and is the voice of 30 million people affected by rare diseases throughout Europe.

    EURORDIS actively participates in the development and implementation of policies to bring real solutions to people living with rare diseases in the areas of prevention, diagnostics, care, research, medicines development, social services, information, education, and more. The organization was founded in 1997. "

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts Jul 16, 2014 7:39 PM Flag

    I posted link at the other site.

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts Jul 15, 2014 12:18 AM Flag

    Insmed has been rising, and one investor is squeezing income from the move.

    optionMONSTER's tracking programs detected the sale of 2,000 July 19 puts for $1.07 and the purchase of 2,000 July 16 puts for $0.22. Volume was below open interest at the lower strike, which suggests an existing short position was closed and rolled up.

    Selling puts lets investors earn income in return for insuring other traders against a drop. If the stock remains above the strike price, they'll keep the premium and the contracts they sold short will expire worthless. But they're at risk of potentially big losses if shares decline. (See our Education section)

    INSM is up 0.16 percent to $19.04 in midday trading and has risen 50 percent in the last month. Most of that move came after the Food and Drug Administration designated its Arikayce lung drug a breakthrough therapy, which opens the door to potentially quicker approval.

    Today's option trader apparently sold the July 16 puts when the stock was lower and has now made money on the bet. Rolling up to the 19 let him or her collect an additional $0.85 and raises the level at which they must get long by $3.

    More than 4,800 contracts have traded so far in the session, more than triple INSM's daily average for the last month.

    Sentiment: Strong Buy

  • checksurshorts checksurshorts Jul 11, 2014 5:51 PM Flag

    "Expanded indications beyond NTM and CF"

    This is important IMO. Yes there are other potential uses for Arikayce but Amikacin is only one of many potential passengers along for a ride in our liposomal rocket-ship...headed for the moon one day I hope.

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts Jul 11, 2014 5:07 PM Flag

    On July 8, 2014, Insmed Incorporated (the “Company”) entered into a Commercialization Agreement (the “Agreement”) with PARI Pharma GmbH (“PARI”) for the manufacture and supply of eFlow nebulizer systems and related accessories (the “Device”) as optimized for use with the Company’s proprietary liposomal amikacin for inhalation. The Agreement has an initial term of fifteen (15) years from the first commercial sale of the Device (the “Initial Term”). The term of the Agreement may be extended by the Company for an additional five (5) years by providing written notice to PARI at the least one (1) year prior to the expiration of the Initial Term. Notwithstanding the foregoing, the parties have certain rights and obligations under the Agreement prior to the commencement of the Initial Term. The Agreement allows for termination by either party upon the occurrence of certain events, including (i) the material breach by the other party of any provision of the Agreement, (ii) the default or bankruptcy of the other party, or (iii) upon termination by the Company of the License Agreement between the parties.

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts Jun 30, 2014 9:19 PM Flag

    Program (Project) Manager - Technical Operations

    Associate Director, Quality Assurance - GCP

    Sentiment: Strong Buy

  • checksurshorts checksurshorts Jun 24, 2014 11:04 PM Flag

    "I did not and will not keep it." Sam, uh, Terry I am.

    Sentiment: Strong Buy

  • Reply to

    Pricing for 6 months of NTM treatment

    by risingedge77 Jun 24, 2014 3:27 PM
    checksurshorts checksurshorts Jun 24, 2014 10:53 PM Flag

    I don't expect you to understand that the main reason the primary endpoint was not reached was a participant ended up (and not due to Arikayce) in the same state as your brain -- dead. And please keep your calculator fetish to yourself.

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts Jun 23, 2014 9:47 PM Flag

    Working in a fast-paced, high energy, entrepreneurial environment, the Director of Clinical Development will play an important role in working with the team to develop strategic clinical approaches for the global clinical development of products. Tasks include assisting on the preparation of clinical development plans, research, and execution, and leading and participating on development teams.

    ◾Collaborate on the development of selected compounds on the implementation of strategies to achieve key objectives and milestones.

    ◾Assist with clinical development planning and oversee trial design and protocol development to achieve optimal speed, quality and economy for the lead programs spanning preclinical through Phase IV include managing activities of clinical research organizations or CROs.

    ◾In cooperation with regulatory co-workers, represent and manage the company’s clinical programs to regulatory authorities and corporate partners lead the preparation of the clinical sections of Regulatory filings.

    ◾Apply a blend of strategic skills combined with a practical, hands-on approach to ensure the timely execution of development plans including oversight of CROs.

    ◾Provide medical and specialty expertise for safety surveillance of clinical studies.

    ◾Build partnerships and relationships with the scientific and medical community including international scientific and professional organizations in the field of Pulmonology and Infectious diseases.

    ◾Working with the senior management team, play a key role in establishing, maintaining and managing collaborations with strategic partners.

    ◾Work closely with business development, technical operation, research, legal and other members of the senior management team to optimize the Company’s intellectual property portfolio, and provide support on technical due diligence and development associated with licensing, acquisitions and collaborations.

    ◾Represent the drug development group externally in scientific presentations, conferences and industry groups.

    ◾Contribute to the positive, success-oriented, high performance culture that reflects Insmed’s values and attracts/retains talent.

    ◾Maintain understanding of competitors and clinical developments in relevant therapeutic areas by attending scientific meetings and tracking literature.

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts Jun 19, 2014 2:38 PM Flag

    "Thought leaders bullish on Insmed data for Arikayce, says Leerink
    Following a call with two key opinion leaders in the Non-Tuberculous Mycobacteria space, Leerink said both specialists' view Insmed 's Arikayce data as "terrific" and were encouraged by yesterday’s breakthrough designation news, though they were hesitant to predict if the FDA will approve the drug on the available data. Leerink reiterates its Outperform rating and $30 price target on Insmed."

    Sentiment: Strong Buy

  • checksurshorts checksurshorts Jun 19, 2014 1:22 AM Flag

    Sigma -

    This is truly a great post. Thank you

    Sentiment: Strong Buy

  • Reply to


    by checksurshorts Jun 18, 2014 12:41 PM
    checksurshorts checksurshorts Jun 18, 2014 12:47 PM Flag

    ID was created yesterday and already over 1500 posts!!!

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts Jun 18, 2014 12:41 PM Flag

    You had better hope you are outside the U.S.

    Sentiment: Strong Buy

  • Reply to


    by biowatchdog Jun 18, 2014 11:00 AM
    checksurshorts checksurshorts Jun 18, 2014 12:07 PM Flag

    Maybe they're just really busy packing up boxes for the move to the new location. LOL

    Sentiment: Strong Buy

  • Reply to

    let's hope our basher isn't using IRS computers

    by zake1 Jun 18, 2014 10:41 AM
    checksurshorts checksurshorts Jun 18, 2014 10:45 AM Flag

    Now that is funny!!!

    Sentiment: Strong Buy

  • Reply to

    Where is the "ignore user" option?

    by mike75x5 Jun 18, 2014 10:40 AM
    checksurshorts checksurshorts Jun 18, 2014 10:43 AM Flag

    Click on flag. Then two options...ignore or report abuse.

17.33-0.28(-1.59%)11:22 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.